Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Imbalances in Cardiac Output

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mind the Gap: Unraveling the Pharmacokinetic Variability of Δ9-Tetrahydrocannabinol (THC).

Journal of clinical pharmacology·2026

Same author

Who gets included? Equity in digital and decentralised mental health and neurodevelopmental trials: A systematic review.

PLOS digital health·2026

Same author

<i>In vivo</i> base editing via single myotrophic adeno-associated viruses in dystrophic mouse muscle and satellite cells.

bioRxiv : the preprint server for biology·2026

Same author

Author Correction: Predicting opioid consumption after surgical discharge: a multinational derivation and validation study using a foundation model.

NPJ digital medicine·2026

Same author

Drug supply chain disruptions and outpatient medication shortages in the Veterans Health Administration, 2017-2020.

Exploratory research in clinical and social pharmacy·2026

Same author

Cellular Functional Analyses of <i>ARX</i> Variants Reveal New Insights Into Genotype-Phenotype Correlations in Neurodevelopmental Disorders Among Male and Female Patients.

Human mutation·2026

Search research articles

Related Experiment Videos

Statins and congestive heart failure.

Jennifer Martin¹

¹Royal Brisbane Women's Hospital Department of Medicine/Diamantina Institute, University of Queensland, 4006, Australia. Jennifer_H_Martin@health.qld.gov.au

Current Atherosclerosis Reports

|August 19, 2008

Summary

This summary is machine-generated.

The Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) found no survival benefit for statin therapy in patients with ischemic systolic heart failure (HF). This challenges previous retrospective findings on statins for HF prevention and treatment.

Related Experiment Videos

Area of Science:

Cardiology
Pharmacology
Clinical Trials

Background:

Post hoc analyses suggest statins benefit heart failure (HF) patients.
Prospective data on statins for HF morbidity and survival were limited before 2007.

Purpose of the Study:

To evaluate the impact of statin therapy on heart failure (HF) morbidity and survival.
To critically assess recent literature on statins in HF, considering potential biases.

Main Methods:

The Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) was a large-scale prospective trial.
The study focused on patients with ischemic systolic HF treated with low-dose rosuvastatin.

Main Results:

The CORONA trial reported no survival benefit in patients with ischemic systolic HF receiving low-dose rosuvastatin.
Existing retrospective data on statins for HF present uncertainties due to potential biases and lack of mechanistic data.

Conclusions:

The CORONA trial results introduce uncertainty regarding statin efficacy in specific HF populations.
Further investigation is needed to clarify the role of statins in heart failure management, addressing data limitations.